Home
Medefil, Inc.

Medefil, Inc. Market Share Analysis for June 2026

Medefil, Inc. was incorporated in 1998 with the focus on addressing the unmet need in the Msaline and heparin flush injectable products.

Industry: N/A

Domainmedefilinc.com

Year Founded1998

Employees51 - 200

Annual Revenue$15M - $25M

Medefil, Inc.

Medefil, Inc. (including company regionals)

medefilinc.com

See more website traffic and engagement information

Medefil, Inc. Revenue up to June 2026 is 15M - 25M

revenue generated by Medefil, Inc. top domains

Medefil, Inc. top domains revenue over 3 years

Revenue for Medefil, Inc. top domains

medefilinc.com15M - 25M

See more with Sales Intelligence

Total visits to Medefil, Inc.'s top domains

Understand Medefil, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

medefilinc.com2.9K

See more with Sales Intelligence

Avg. visit duration in Medefil, Inc.'s top domains

Analyze Medefil, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

medefilinc.com00:00:36

See more with Sales Intelligence

Avg. pageviews on Medefil, Inc.'s top domains

See how Medefil, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

medefilinc.com1.75

See more with Sales Intelligence

Medefil, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Medefil, Inc.

These are the website technologies, by industry, used by Medefil, Inc. top domains

Widget (4)

Twemoji

Mobile (2)

Meta Viewport

Content Management System (1)

WordPress

Conversion & Analytics (1)

Google Analytics

More Technologies

3

See all

News & Signals from Medefil, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMedefil Inc. has issues with violations of the Illinois Biometric Information Privacy Act.Medefil, Inc. has agreed to settle a class action lawsuit alleging violations of the Illinois Biometric Information Privacy Act (BIPA).

NewsMedefil Inc. launched FDA-approved ANDA products, Atropine Sulfate Injection, USP, 1 mg per 10 mL on Dec 4th '23.Medefil, Inc., a domestic manufacturer of injectable products, has announced availability of its FDA-approved ANDA products, Atropine Sulfate Injection, USP, 1 mg per 10 mL (0.1 mg/mL), and 10% Calcium Chloride Injection, USP, 1000 mg per 10 mL (100 mg/mL).